Progress in immunoconjugate cancer therapeutics

Advances in immunoconjugate technology have revitalized the “magic bullet” concept of immunotherapeutics for the treatment of cancer. The growing availability of “human” antibodies, the increased epitope repertoire due to genomics and proteomics efforts, and advances in the means of identification a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer cell 2003-03, Vol.3 (3), p.207-212
1. Verfasser: Payne, Gillian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Advances in immunoconjugate technology have revitalized the “magic bullet” concept of immunotherapeutics for the treatment of cancer. The growing availability of “human” antibodies, the increased epitope repertoire due to genomics and proteomics efforts, and advances in the means of identification and production of tumor-specific antibodies have greatly increased the potential for cancer therapeutic opportunities. Furthermore, the realization that effector molecule potency must be sufficiently high to be effective at concentrations that might realistically be delivered to the tumor site on an antibody carrier has greatly spurred the fields of medicinal chemistry and radionuclide chelate chemistry to produce such molecules.
ISSN:1535-6108
1878-3686
DOI:10.1016/S1535-6108(03)00057-6